Today, the Ways and Means Committee convened a hearing to examine drug shortages, supply chain resiliency, and the impact of shortages on providers. The hearing echoed previous Congressional discourse on the topic by focusing on generic sterile injectables, especially cancer drugs cisplatin and carboplatin. Members and witnesses explored policies to prevent shortages such as increasing transparency, incentivizing quality in manufacturing,… (Marceno, February 6, 2024) #Food and Drug Administration, #Generic Drugs, #Public Health